Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity

References

• Quinn GE, Gilbert C, Darlow BA, Zin A. Retinopathy of prematurity: an epidemic in the making. Chin Med J (Engl) 2010;123:2929–2937
   PubMed Web of Science ®Google Scholar
• Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 2006;26:S11–S15
   Google Scholar
• O’Keefe M, Lanigan B, Long VW. Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 2003;81:614–616
   Google Scholar
• Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina 2010;30:S37–S40
   PubMedGoogle Scholar
• Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738–4747
   PubMed Web of Science ®Google Scholar
• Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536–543
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603–615
   PubMed Web of Science ®Google Scholar
• Hard AL, Hellström A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011;100:1063–1065
   Google Scholar
• Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013;98:F170–F174
   PubMed Web of Science ®Google Scholar
• Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP? Invest Ophthalmol Vis Sci 2011;52:9288–9289
   PubMed Web of Science ®Google Scholar
• Bayley N. Bayley Scales of Infant and Toddler Development. San Antonio, TX: The Psychological Corporation; 2006
   Google Scholar
• Leonard CH, Piecuch RE, Cooper BA. Use of the Bayley Infant Neurodevelopmental Screener with low birth weight infants. J Pediatr Psychol 2001;26:33–40
   Google Scholar
• Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 2011;27:379–383
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695–1705
   PubMed Web of Science ®Google Scholar
• al-Dhibi H, Khan A. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS 2009;13:400–402
   Google Scholar
• Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al.Pan merican Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81–87
   PubMed Web of Science ®Google Scholar
• Cakir M, Cekic O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 2008;12:309–311
   Google Scholar
• Quiram PA, Drenser KA, Lai MM, Capone A, Trese MT. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina 2008;28:S8–S12
   Google Scholar
• Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA. Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Semin Ophthalmol 2009;24:70–76
   Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333
   PubMed Web of Science ®Google Scholar
• Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol 2013;131:1099–1101
   Google Scholar
• Hard AL, Hellström A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011;100:1063–1065
   Google Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155:1119–1124
   PubMed Web of Science ®Google Scholar
• Hard AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review. Acta Paediatr 2011;100:1523–1527
   PubMed Web of Science ®Google Scholar
• Dezoete JA, MacArthur BA, Tuck B. Prediction of Bayley and Stanford-Binet scores with a group of very low birthweight children. Child Care Health Dev 2003;29:367–372
   PubMedGoogle Scholar
• Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, Ramírez-Moreno MA, Morales-Cruz MV. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cir Cir 2011;79:207–214, 225–32. [Article in Spanish]
   Google Scholar
• Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed 2013;98:F327–F333
   Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95–113
   PubMed Web of Science ®Google Scholar
• Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol. 2013. [Epub ahead of print]. doi: 10.1111/aos.12266
   Google Scholar
• Goyen TA, Lui K. Longitudinal motor development of “apparently normal” high-risk infants at 18 months, 3 and 5 years. Early Hum Dev. 2002;70:103–115
   PubMed Web of Science ®Google Scholar